As a master’s student, Fabio worked on the development of cholinergic nervous system drugs at the University of Wuerzburg (Germany). In 2016, he joined the pharmaceutical company GlaxoSmithKline in Siena (Italy), where he developed multivalent glycoconjugate vaccines for injectable administration.

Subsequently, his research interests geared towards precision medicine, and he obtained a PhD in Medicinal Chemistry (2020) at the Institute for Bioengineering of Catalonia in Barcelona (Spain), where he worked in developing light-regulated drugs for the treatment of cardiovascular diseases and neurological disorders. Most of his work has been published in peer-reviewed journals.